|Healthcare Review: Chelsea Therapeutics International Ltd, Idera Pharmaceuticals Inc, Ampio Pharmaceuticals Inc, Horizon Pharma Inc., Arrowhead Research Corp.|
|By Staff and Wire Reports|
|Thursday, 08 May 2014 12:37|
Idera Pharmaceuticals Inc ($IDRA)’s shares jumped 5.62% to $2.63 after the company announced that it has entered into an agreement with Abbott (ABT), the global healthcare company, for the development of an in vitro companion diagnostic test for use in Idera’s clinical development programs to treat certain genetically defined forms of B-cell lymphoma with IMO-8400.
Ampio Pharmaceuticals Inc ($AMPE)’s shares soared 16.87% to $6.79. Citigroup Inc. assumed coverage on shares of Ampio Pharmaceuticals ($AMPE) in a research note issued on Thursday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.
Horizon Pharma Inc ($HZNP)’s shares added 4.18% to $13.96. Horizon Pharma, Inc. operates as a biopharmaceutical company. It is focused on developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.
Arrowhead Research Corp ($ARWR)’s shares gained 4.09% to $10.19. Recently, Zacks reaffirmed their outperform rating on shares of Arrowhead Research Corp (ARWR) in a report issued on Tuesday, Analyst Ratings Network.com reports. They currently have an $18.75 target price on the stock.